<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62866">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287493</url>
  </required_header>
  <id_info>
    <org_study_id>PV4244</org_study_id>
    <nct_id>NCT02287493</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Selected Antiinfectives During Sustained Low-efficiency Dialysis (SLED)</brief_title>
  <acronym>PhA-SLED</acronym>
  <official_title>Pharmacokinetics of Selected Antiinfectives During Sustained Low-efficiency Dialysis (SLED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a prospective, non-interventional, monocentric observational study the pharmacokinetic
      properties of selected antiinfective drugs during sustained low-efficiency dialysis (SLED)
      will be analyzed.

      Plasma specimens will be quantified using high Performance liquid chromatography (HPLC).

      Primary endpoint: Plasma levels of antiinfectives during SLED

      Secondary endpoints:

        -  28-day-mortality

        -  length of stay at the intensive care unit (ICU) and in hospital

        -  clinical and microbiological cure of infections

      Inclusion criteria:

        -  age: &gt; 18 years

        -  patients under SLED

        -  antiinfective treatment

      exclusion criteria:

      - missing informed consent
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum levels of meropenem or ceftazidim during SLED</measure>
    <time_frame>Pharmacokinetic measures (days 1, 3, 5 and at the end of SLED; 0, 1, 2, 4h after start of SLED and at the end of SLED))</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>28-day mortality, for inpatients</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay at the ICU and in hospital</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and microbiological cure of infections</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Replacement Therapy, Renal</condition>
  <arm_group>
    <arm_group_label>Meropenem</arm_group_label>
    <description>Adult ICU patients receiving meropenem during SLED will be analyzed for meropenem pharmacokinetics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ceftazidim</arm_group_label>
    <description>Adult ICU patients receiving ceftazidim during SLED will be analyzed for ceftazidim pharmacokinetics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacokinetic Analysis</intervention_name>
    <arm_group_label>Meropenem</arm_group_label>
    <arm_group_label>Ceftazidim</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult ICU patients at University Medical Center Hamburg-Eppendorf receiving SLED and
        either meropenem or ceftazidim.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age: 18 or older

          -  patients receiving SLED and either meropenem or ceftazidim

        Exclusion Criteria:

          -  missing informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Kluge, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Hamburg-Eppendorf, Department of Intensive Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 12, 2016</lastchanged_date>
  <firstreceived_date>October 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Stefan Kluge</investigator_full_name>
    <investigator_title>Director of the Department of Intensive Care</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
